locally advanced unresectable pancreatic cancer
Conditions
Interventions
Patients receiving nab-PTX plus gemcitabine will receive 125 mg/m2, nab-PTX as a 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30-
Sponsors
Kurume university school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histlogically proven adenocarcinoma or adeno-squamous carcinoma 2) Unresectable locally advanced pancreatic cancer 3) No prior chemotherapy and radiotherapy for other malignancies 4) Age upper 20 and less than 80 5) ECOG performance status of 0, 1 6) Adequate hematologic, hepatic and renal function 7) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with Distant metastasis 2) Patients with symptomatic pulmonary fibrosis or interstitial pneumonia 3) Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. 4) Patients has severe complications, such as heart failure, renal failure ileus and severe mental disorder 5) History of malignancy in the last 3 years 6) History of Peripheral Artery Disease (eg, claudication, Leo Buerger's disease). 7) History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa). 8) Women who are pregnant or expect to be pregnant, or nursing female 9) Others
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression free survival, adverse events | — |
Countries
Japan
Contacts
Public ContactMasaru Fukahori
Kurume university school of medicine Division of gastroenterology, multidisciplinary cancer treatment center
Outcome results
None listed